All media enquiries:

Cognito Therapeutics Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2021

July 14, 2021

Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board

July 6, 2021

Cognito Therapeutics Initiates Studies in Down Syndrome Associated Alzheimer’s Disease

June 14, 2021

Cognito Therapeutics Appoints Everett Crosland as Chief Commercial Officer

May 18, 2021

Cognito Therapeutics Appoints Jonathan Lieber as Chief Financial Officer

May 5, 2021

Cognito Therapeutics to Advance Digital Therapeutic for Alzheimer’s into Pivotal Studies Based on Positive Clinical Results Announced at AD/PD 2021

March 17, 2021

Announcing Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer’s Disease

March 9, 2021

Cognito Therapeutics to Announce New Clinical Data Evaluating Gamma Frequency Neuromodulation to Treat Alzheimer’s Disease at 2021 AD/PD Virtual Conference

March 2, 2021

Cognito Therapeutics Receives FDA Breakthrough Device Designation for Next-Generation Digital Therapeutic in Alzheimer’s Disease

January 12, 2021